260 related articles for article (PubMed ID: 33113628)
21. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
Lyman G; Lalla A; Barron R; Dubois RW
Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
[TBL] [Abstract][Full Text] [Related]
22. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
Shi YK; Liu P; Yang S; Han XH; He XH; Ai B; Qin Y; Li B; Huang DZ; Zhang CG; Sun Y
Ai Zheng; 2006 Apr; 25(4):495-500. PubMed ID: 16613688
[TBL] [Abstract][Full Text] [Related]
23. [A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
Xu B; Tian F; Yu J; Song Y; Shi J; Zhang B; Zhang Y; Yuan Z; Wu Q; Zhang Q; Nan K; Sun Q; Li W; Hu J; Bi J; Meng C; Dai H; Jiang H; Yue S; Cao B; Sun Y; Wang S; Tong Z; Shen P; Wu G; Tang L; Deng Y; Jia L; Shen K; Zhuang W; Xie X; Wu Y; Chen L
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):23-7. PubMed ID: 26796802
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
Jiang Y; Zhang J; Zhong J; Liao H; Zhang J; Liu Y; Liang Y; Li H
BMC Cancer; 2023 Jul; 23(1):702. PubMed ID: 37495949
[TBL] [Abstract][Full Text] [Related]
25. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
26. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
Griffiths RI; Barron RL; Gleeson ML; Danese MD; O'Hagan A; Chia VM; Legg JC; Lyman GH
Pharmacoeconomics; 2012 Feb; 30(2):103-18. PubMed ID: 21967155
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte-colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study.
Liu C; Hao Y; Wang L; Meng F; Wen F; Zhong D
Thorac Cancer; 2021 Apr; 12(8):1154-1161. PubMed ID: 33590721
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan.
Tseng TH; Chiang SC; Hsu JC; Ko Y
PLoS One; 2024; 19(6):e0303294. PubMed ID: 38857244
[TBL] [Abstract][Full Text] [Related]
29. Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study.
Wang Y; Zhao C; Ma P; Jiang D
Cancer Control; 2023; 30():10732748221140289. PubMed ID: 36598048
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
[TBL] [Abstract][Full Text] [Related]
31. [The role of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) in breast cancer receiving adjuvant chemotherapy].
Zhang JY; Liu YX; Wang H; Mi L; Song GH; Jiang HF; Yan Y; Shao B; Kong WY; Zhang RY; Ran R; Liu XR; Wang J; Lin YT; Li HP
Zhonghua Yi Xue Za Zhi; 2018 Sep; 98(34):2718-2721. PubMed ID: 30220167
[No Abstract] [Full Text] [Related]
32. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
[TBL] [Abstract][Full Text] [Related]
33. [Application of pegylated recombinant human granulocyte colony-stimulating factor to prevent chemotherapy-induced neutropenia in patients with lymphoma: a prospective, multicenter, open-label clinical trial].
Huang HQ; Bai B; Gao YH; Zou DH; Zou SH; Tan H; Song YP; Li ZY; Jin J; Li W; Su H; Gong YP; Zhong MZ; Shuang YR; Zhu J; Zhang JQ; Cai Z; Teng QL; Sun WJ; Yang Y; Xia ZJ; Chen HL; Hua LM; Bao YY; Wu N
Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):825-830. PubMed ID: 29166732
[No Abstract] [Full Text] [Related]
34. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
[TBL] [Abstract][Full Text] [Related]
36. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.
Ji X; Xu L; Pan P; Xu Z; Wang A; Li Y
Thorac Cancer; 2022 Jan; 13(1):117-125. PubMed ID: 34791805
[TBL] [Abstract][Full Text] [Related]
38. Pegylated recombinant human granulocyte colony-stimulating factor regulates the immune status of patients with small cell lung cancer.
Sun J; Bai H; Wang Z; Duan J; Li J; Guo R; Wang J
Thorac Cancer; 2020 Mar; 11(3):713-722. PubMed ID: 32020764
[TBL] [Abstract][Full Text] [Related]
39. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
Huang W; Liu J; Zeng Y; Wu F; Li N; Chen K; Hong Y; Wang L; Zhen H; Lin L
Cancer Chemother Pharmacol; 2018 Oct; 82(4):607-613. PubMed ID: 30043207
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Primary and Secondary Prophylaxis Using PEGylated Recombinant Human Granulocyte-Stimulating Factor as a Cost-Effective Measure in Malignant Neoplasms: A Multicenter Retrospective Study.
Wu Q; Li Q; Zhang J; Luo Z; Zhou J; Chen J; Luo Y
Front Pharmacol; 2021; 12():690874. PubMed ID: 34776940
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
